We have performed the additional analysis including aspartate aminotransferase platelet ratio (APRI) and albumin-bilirubin (ALBI) score. In the univariable analysis, hazard ratios (HR) (95% confidence interval [CI]) of APRI (per 1 point increase) for hepatocellular carcinoma development (HCC), decompensation and mortality were 1.42 (1.3-1.6), 1.24 (1.2-1.3) and 1.22 (1.2-1.3), respectively, and APRI was significantly associated with HCC, decompensation and mortality. Similarly, HRs (95% CI) of ALBI score (per 1 point increase) for HCC, decompensation and mortality were 2. 45 (1.8-3.4), 4.44 (3.7-5.4) and 3.81 (3.2-4.6), respectively, and ALBI score was also associated with complication development and mortality. In the multivariable analysis, including age, gender, aetiology of liver disease, diabetes mellitus, dyslipidaemia, hypertension, history of complications (only for mortality), APRI and ALBI, adjusted HRs of magnetic resonance elastography (MRE)-associated liver stiffness